Keytruda and Opdivo: a decade review
Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and respective HTA evaluations.
Pricing and Market Access
US negotiations for first round of drugs reveal $6bn in Medicare savings
Colombia’s president signs law to strengthen pharmaceutical sector
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy
The US Biosecure Act threatens to destabilise the pharmaceutical industry
UK’s antibiotic subscription funding model – a route to market sustainability?
Ukraine: a market access review over two years of war
AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs
